NWS
77
8
EXC
47
2
ADM
36
2
RRC
46
-2
PM
52
-4
TROW
48
-2
BMY
43
8
AMAT
60
-4
VFC
45
3
ALL
45
-3
HRL
29
2
CAG
39
5
ACN
65
4
HPE
46
-5
NWL
32
4
INTC
47
6
RL
76
-3
IPG
42
-2
CHK
5
-7
LYB
32
2
NWS
77
8
EXC
47
2
ADM
36
2
RRC
46
-2
PM
52
-4
TROW
48
-2
BMY
43
8
AMAT
60
-4
VFC
45
3
ALL
45
-3
HRL
29
2
CAG
39
5
ACN
65
4
HPE
46
-5
NWL
32
4
INTC
47
6
RL
76
-3
IPG
42
-2
CHK
5
-7
LYB
32
2
Financhill
Back

Ultragenyx Pharmaceutical Quote, Financials, Valuation and Earnings

Sell
43

RARE
Ultragenyx Pharmaceutical

Last Price:
39.58
Seasonality Move:
3.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Ultragenyx Pharmaceutical Price Quote

$39.58
-0.02 (4.1%)
(Updated: June 22, 2024 at 5:45 AM ET)

Ultragenyx Pharmaceutical Key Stats

Sell
43
Ultragenyx Pharmaceutical (RARE) is a Sell
Day range:
$38.24 - $39.64
52-week range:
$31.52 - $54.56
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.89
P/B ratio:
25.57%
Volume:
766.3K
Avg. volume:
881.8K
1-year change:
-24.07%
Market cap:
$3.6B
Revenue:
$434.2M
EPS:
$-8.03

How Much Does Ultragenyx Pharmaceutical Make?

Is Ultragenyx Pharmaceutical Growing As A Company?

Ultragenyx Pharmaceutical Stock Price Performance

What Is Ultragenyx Pharmaceutical 52-Week High & Low?

Ultragenyx Pharmaceutical Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ultragenyx Pharmaceutical?

Is Ultragenyx Pharmaceutical Cash Flow Positive?

  • What Is RARE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$508.7M
  • What Is Ultragenyx Pharmaceutical’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $388.8M
  • What Is Ultragenyx Pharmaceutical’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $151.1M

Ultragenyx Pharmaceutical Return On Invested Capital

  • Is Management Doing A Good Job?
    RARE return on invested capital is -384.83%
  • What Is Ultragenyx Pharmaceutical Return On Assets?
    ROA measures how assets are converting to revenues and is -45.56%
  • What Is RARE Return On Equity?
    ROE is a measure of profitability and is -384.83%

Ultragenyx Pharmaceutical Earnings Date & Stock Price

Ultragenyx Pharmaceutical Competitors

Ultragenyx Pharmaceutical Dividend Yield

Data Unavailable

Ultragenyx Pharmaceutical Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -18.01%
Revenue: 8.3% -6.53%

Analyst Recommendations

Buy Recommendations: 13
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 90.05
Upside from Last Price: 127.39%

Major Shareholders

  • How many RARE shares are owned by institutional investors?
    122.9M RARE shares are owned by institutional investors
  • How many RARE shares are owned by insiders?
    1.8M RARE shares are owned by insiders